Analysts Offer Predictions for Sutro Biopharma Q1 Earnings

Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - HC Wainwright increased their Q1 2025 earnings per share estimates for shares of Sutro Biopharma in a report issued on Monday, March 17th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.38) per share for the quarter, up from their previous forecast of ($0.82). HC Wainwright has a "Neutral" rating and a $2.00 price target on the stock. The consensus estimate for Sutro Biopharma's current full-year earnings is ($2.92) per share. HC Wainwright also issued estimates for Sutro Biopharma's Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.68) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.17) EPS, FY2028 earnings at ($0.13) EPS and FY2029 earnings at ($0.09) EPS.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($2.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($2.10). The company had revenue of $14.00 million during the quarter, compared to analyst estimates of $10.44 million. Sutro Biopharma had a negative net margin of 77.01% and a negative return on equity of 101.89%. During the same quarter last year, the firm earned ($1.78) EPS.

A number of other research analysts have also issued reports on STRO. Citizens Jmp lowered shares of Sutro Biopharma from an "outperform" rating to a "market perform" rating in a research note on Friday, March 14th. Piper Sandler set a $2.00 price target on shares of Sutro Biopharma in a research note on Friday, March 14th. Bank of America cut shares of Sutro Biopharma from a "buy" rating to an "underperform" rating and lowered their price target for the stock from $11.00 to $1.00 in a research note on Friday, March 14th. Wedbush cut shares of Sutro Biopharma from an "outperform" rating to a "neutral" rating and lowered their price target for the stock from $8.00 to $2.00 in a research note on Friday, March 14th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $17.00 price target on shares of Sutro Biopharma in a research note on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $6.63.

Remove Ads

Sutro Biopharma Trading Down 3.7 %

Shares of Sutro Biopharma stock traded down $0.03 on Wednesday, reaching $0.77. 1,776,000 shares of the stock were exchanged, compared to its average volume of 972,631. Sutro Biopharma has a 1-year low of $0.76 and a 1-year high of $6.13. The business has a fifty day moving average price of $1.64 and a two-hundred day moving average price of $2.61. The firm has a market capitalization of $63.24 million, a PE ratio of -0.48 and a beta of 1.22.

Institutional Trading of Sutro Biopharma

Several large investors have recently bought and sold shares of STRO. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Sutro Biopharma in the fourth quarter valued at $26,000. China Universal Asset Management Co. Ltd. purchased a new stake in Sutro Biopharma during the 4th quarter worth about $32,000. Vontobel Holding Ltd. increased its position in Sutro Biopharma by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company's stock worth $46,000 after purchasing an additional 10,000 shares in the last quarter. ProShare Advisors LLC increased its position in Sutro Biopharma by 74.3% during the 4th quarter. ProShare Advisors LLC now owns 26,961 shares of the company's stock worth $50,000 after purchasing an additional 11,494 shares in the last quarter. Finally, Velan Capital Investment Management LP purchased a new stake in Sutro Biopharma during the 4th quarter worth about $55,000. Institutional investors and hedge funds own 96.99% of the company's stock.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.